Rolando Atiga, MD
Family Medicine · Murrieta, CANPI 1275527152
Payments from drug & device makers
Across 156 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$423
- GSK$363
- Boehringer Ingelheim$211
- Novo Nordisk$205
- Lilly USA, LLC$191
- Amgen$127
- plus $2K from 36 others
What the payments were for
- Food & beverage$3,272100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $423 |
| GSK | 18 | $363 |
| Boehringer Ingelheim | 10 | $211 |
| Novo Nordisk | 9 | $205 |
| Lilly USA, LLC | 10 | $191 |
| Amgen | 6 | $127 |
| Sumitomo Pharma America, Inc. | 5 | $125 |
| AbbVie | 5 | $118 |
| Pfizer | 8 | $115 |
| Exact Sciences | 6 | $108 |
| Abbott | 4 | $93 |
| Collegium Pharmaceutical, Inc. | 4 | $85 |
| Merck | 5 | $84 |
| Hologic Sales And Service, LLC | 4 | $83 |
| Optinose US, Inc. | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 2 | $71 |
| Johnson & Johnson | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 2 | $57 |
| Medtronic | 2 | $52 |
| Verity Pharmaceuticals Inc. | 2 | $49 |
| Edwards Lifesciences | 2 | $45 |
| Mannkind Corporation | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Boston Scientific | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| TMS Neurohealth Centers Inc. | 2 | $31 |
| Bayer | 1 | $29 |
| Beone Medicines USA, Inc. | 1 | $28 |
| Dexcom, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Evoke Pharma, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$3,272 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 149 | $183,792 |
| OzempicSemaglutide | 108 | $119,291 |
| JanuviaSitagliptin Phosphate | 49 | $62,706 |
| EliquisApixaban | 59 | $51,587 |
| XareltoRivaroxaban | 26 | $31,368 |
| RybelsusSemaglutide | 25 | $28,112 |
| TrulicityDulaglutide | 22 | $20,787 |
| InvokanaCanagliflozin | 19 | $20,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $20,202 |
| EntrestoSacubitril/Valsartan | 12 | $10,109 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $10,019 |
| FarxigaDapagliflozin Propanediol | 11 | $9,479 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $8,046 |
| Potassium Chloride | 23 | $7,172 |
| Atorvastatin Calcium | 581 | $5,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $211 | $183,792149 claims |
| Novo NordiskOzempic, Rybelsus | $205 | $147,403133 claims |
| MerckJanuvia | $84 | $62,70649 claims |
| Johnson & JohnsonXarelto, Invokana | $65 | $52,00245 claims |
| PfizerEliquis | $115 | $51,58759 claims |
| Lilly USA, LLCTrulicity | $191 | $20,78722 claims |
| GSKTrelegy Ellipta | $363 | $20,20224 claims |
| AstraZenecaFarxiga | $423 | $9,47911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Murrieta
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.